ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
press release announcing its financial results for the fiscal
year ended December 31, 2016. A copy of the press release is
furnished herewith as Exhibit 99.1.*
|
Exhibit No.
|
Description
|
|
99.1
|
ADMA Biologics, Inc. Press Release, dated February 24,
2017. |
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease. ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Recent Trading Information
ADMA BIOLOGICS, INC. (NASDAQ:ADMA) closed its last trading session up +0.01 at 4.79 with 30,955 shares trading hands.
